Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
Randomized, Open, Multicenter, Prospective, Phase II Clinical Trial of Doxorubicin vs. Trabectedin Plus Doxorubicin in the First Line Treatment of Patients With Advanced Non Operable and/or Metastatic Soft Tissue Sarcomas
Sponsor: Grupo Espanol de Investigacion en Sarcomas
Terminated
Interim analysis did not show good results for main objective
Other Sarcoma trials with similar outcome
A PHASE2 clinical study on Sarcoma, this trial is terminated or withdrawn. The trial is conducted by Grupo Espanol de Investigacion en Sarcomas and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grupo Espanol de Investigacion en Sarcomas
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badalona, Spain , Barcelona, Spain , Castellon, Spain , Girona, Spain , L'Hospitalet de Llobregat, Spain , Lugo, Spain , Madrid, Spain , Málaga, Spain , Navarra, Spain , Oviedo, Spain and 5 more locations